The Bey laboratory’s primary disease focus is lung cancer. Lung cancer is the leading cause of cancer related deaths in the U.S. and worldwide. The 5-year lung cancer patient survival rate in the U.S. is less than 20% and the incidence of lung cancer in Appalachian States, such as West Virginia and Kentucky, is higher than the national average. Thus, developing novel treatment strategies and discovering more clinically relevant, targeted and less toxic therapeutics is desperately needed. The Bey laboratory is interested in investigating specific genes that regulate oxidative stress and elucidating the role that these genes play in the process of tumorigenesis.
The primary preclinical methodologies used in our investigations include the use of the WVU-HS imaging core for in vivo tumor imaging of luciferase tagged tumor cells and in vivo stereotatic irradiation for precise focused tumor irradiation experimentation. Our laboratory also utilizes nanoparticles for therapeutic drug delivery (in collaboration with Dr. Werner Geldenhuys, Department of Pharmaceutical Sciences) and experimental models of lung tumor metastasis to the brain (in collaboration with Dr. Paul Lockman, Chair of Pharmaceutical Sciences). The laboratory is funded through grants from WVU-Clinical and Translational Science Institute, the Allen Lung Cancer Foundation and the generous support of the School of Pharmacy and the WVU-Cancer Institute.